Literature DB >> 15927833

Concentration of histamine in serum and tissues of the primary ductal breast cancers in women.

K Sieja1, S Stanosz, J von Mach-Szczypiński, S Olewniczak, M Stanosz.   

Abstract

The aim of this study was to evaluate the concentration of histamine (HA) and the activities of their enzymes, namely histidine decarboxylase (HDC) and diaminooxydase (DAO) in 95 women with ductal breast cancer and in healthy women. The control group comprised 60 women without any pathological changes in their breasts, in whom mammoplasties were performed. In women with breast cancer the concentration of HA in serum was significantly higher than in healthy controls (9.1+/-3.2 vs. 5.9+/-3.1 nmol/l; P<0.001). The concentration of HA was significantly higher in neoplasmatic tissues of women with breast cancers than in unchanged tissues of healthy subjects in the control group (14.2+/-5.1 vs. 6.3+/-9.1 nmol/g; P<0.001). HDC activity was significantly elevated in cancerous tissues of women with breast cancer relative to unchanged tissues of healthy subjects (54.7+/-17.1 vs. 39.3+/-26.9 pmol/min per mg; P<0.01). However, the activity of DAO was significantly lower (14.0+/-0.4 vs. 36.1+/-9.7 pmol/min per mg; P<0.001) in neoplasmatic tissues than in normal tissues of healthy women. The adjacent healthy tissue of cancer revealed higher concentrations of HA than were found in unchanged tissues of healthy subjects (6.3+/-9.1 vs. 7.5+/-5.4 pmol/min per mg), but this difference did not reach statistical significance. The activity of HDC did not show any significant difference between the healthy tissues adjacent to cancer foci of women with breast cancer and normal tissues obtained from healthy subjects (39.3+/-26.9 vs. 34.5+/-24.3 pmol/min per mg). However, the activity of DAO was markedly lower than in unchanged tissues of healthy women in the control group (36.1+/-9.7 vs. 14.4+/-10.9 pmol/min per mg; P<0.001). The concentration of HA in cancerous tissues was significantly higher than in adjacent healthy tissues (14.2+/-5.1 vs. 7.5+/-5.4 nmol/g; P<0.001). The activity of HDC was significantly higher in cancerous tissues than in adjacent healthy tissues (54.7+/-17.1 vs. 34.5+/-24.3 pmol/min per mg; P<0.001), but there was no difference in the activity of DAO (14.0+/-6.4 vs. 14.4+/-10.9 pmol/min per mg). The significant elevation of HA concentration in cancerous tissues of women with the ductal breast cancers is caused by the increased synthesis and decreased inactivation of HA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15927833     DOI: 10.1016/j.breast.2004.06.012

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  11 in total

1.  Histamine reduces susceptibility to natural killer cells via down-regulation of NKG2D ligands on human monocytic leukaemia THP-1 cells.

Authors:  Yasuhiro Nagai; Yukinori Tanaka; Toshinobu Kuroishi; Ryutaro Sato; Yasuo Endo; Shunji Sugawara
Journal:  Immunology       Date:  2012-05       Impact factor: 7.397

Review 2.  Histamine receptors and cancer pharmacology: an update.

Authors:  Noelia A Massari; Melisa B Nicoud; Vanina A Medina
Journal:  Br J Pharmacol       Date:  2018-12-13       Impact factor: 8.739

Review 3.  Histamine receptors and cancer pharmacology.

Authors:  Vanina A Medina; Elena S Rivera
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

4.  The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1.

Authors:  Hongzhong Li; Yi Xiao; Qin Li; Jun Yao; Xiangliang Yuan; Yuan Zhang; Xuedong Yin; Yohei Saito; Huihui Fan; Ping Li; Wen-Ling Kuo; Angela Halpin; Don L Gibbons; Hideo Yagita; Zhongming Zhao; Da Pang; Guosheng Ren; Cassian Yee; J Jack Lee; Dihua Yu
Journal:  Cancer Cell       Date:  2021-11-24       Impact factor: 31.743

5.  Integrated Network Pharmacology Approach for Drug Combination Discovery: A Multi-Cancer Case Study.

Authors:  Antonio Federico; Michele Fratello; Giovanni Scala; Lena Möbus; Alisa Pavel; Giusy Del Giudice; Michele Ceccarelli; Valerio Costa; Alfredo Ciccodicola; Vittorio Fortino; Angela Serra; Dario Greco
Journal:  Cancers (Basel)       Date:  2022-04-18       Impact factor: 6.575

6.  The impact of ranitidine on monocyte responses in the context of solid tumors.

Authors:  Ava Vila-Leahey; Dakota Rogers; Jean S Marshall
Journal:  Oncotarget       Date:  2016-03-08

7.  Upregulation of histamine receptor H1 promotes tumor progression and contributes to poor prognosis in hepatocellular carcinoma.

Authors:  Jing Zhao; Yiran Hou; Chun Yin; Jing Hu; Tian Gao; Xiaojun Huang; Xiaohong Zhang; Jinliang Xing; Jiaze An; Shaogui Wan; Jibin Li
Journal:  Oncogene       Date:  2019-11-18       Impact factor: 9.867

8.  Associations of polymorphisms in histidine decarboxylase, histamine N-methyltransferase and histamine receptor H3 genes with breast cancer.

Authors:  Gong-Hao He; Jia-Ji Lin; Wen-Ke Cai; Wen-Mang Xu; Zheng-Ping Yu; Sun-Jun Yin; Can-Hu Zhao; Gui-Li Xu
Journal:  PLoS One       Date:  2014-05-16       Impact factor: 3.240

Review 9.  Allergy-Related Diseases and Risk of Breast Cancer: The Role of Skewed Immune System on This Association.

Authors:  Fatemeh Sadeghi; Mohammad Shirkhoda
Journal:  Allergy Rhinol (Providence)       Date:  2019-07-22

10.  The role of H1 antihistamines in contralateral breast cancer: a Danish nationwide cohort study.

Authors:  Annet Bens; Christian Dehlendorff; Søren Friis; Deirdre Cronin-Fenton; Maj-Britt Jensen; Bent Ejlertsen; Timothy L Lash; Niels Kroman; Lene Mellemkjær
Journal:  Br J Cancer       Date:  2020-02-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.